We report a high incidence of neutropenia in patients treated with rituximab prior to and following autologous stem cell transplantation (ASCT). Fourteen patients with follicular or mantle-cell lymphoma were treated with high dose (HD) therapy followed by an in vivo-purged autologous graft. Ten of these patients received two additional courses of rituximab after the transplant. Seven experienced severe neutropenia after the second administration. Our data suggest that early administration of rituximab following a transplant may favor the onset of neutropenia.
Cairoli, R., Grillo, G., Tedeschi, A., D'Avanzo, G., Marenco, P., Morra, E. (2004). High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. HAEMATOLOGICA, 89(3), 361-363.
High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation
Cairoli R
;
2004
Abstract
We report a high incidence of neutropenia in patients treated with rituximab prior to and following autologous stem cell transplantation (ASCT). Fourteen patients with follicular or mantle-cell lymphoma were treated with high dose (HD) therapy followed by an in vivo-purged autologous graft. Ten of these patients received two additional courses of rituximab after the transplant. Seven experienced severe neutropenia after the second administration. Our data suggest that early administration of rituximab following a transplant may favor the onset of neutropenia.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Cairoli-2004-Haematologica-VoR.pdf
Solo gestori archivio
Descrizione: Letter to the Editor
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Licenza:
Tutti i diritti riservati
Dimensione
201.37 kB
Formato
Adobe PDF
|
201.37 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
